We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
Cap. Flow
+$71.5M
Cap. Flow %
2.43%
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12
Avg Time Held
0.9 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$85.5M
2
QURE icon
uniQure
QURE
+$52M
3
LH icon
Labcorp
LH
+$50.7M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$46.9M
5
IFRX icon
InflaRx
IFRX
+$40.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$78.7M
2
PBYI icon
Puma Biotechnology
PBYI
+$74.6M
3
PEN icon
Penumbra
PEN
+$67.6M
4
ABT icon
Abbott
ABT
+$39.2M
5
RGNX icon
Regenxbio
RGNX
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.2%
2 Miscellaneous 1.77%
3 Financials 1.03%
4 Technology 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SGRY icon
51
Surgery Partners
SGRY
$1.98B
$9.26M 0.31%
+621,300
New +$10.4M
2018 Q2
0 quarters
STIM icon
52
Neuronetics
STIM
$141M
$7.98M 0.27%
+300,000
New +$8.16M
2018 Q2
0 quarters
LUMO icon
53
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$7.67M 0.26%
179,083
-49,161
-22% -$2.25M
2017 Q3
3 quarters
IMUX icon
54
Immunic
IMUX
$94.1M
$7.5M 0.25%
+2,738
New +$6.33M
2018 Q2
0 quarters
INSP icon
55
Inspire Medical Systems
INSP
$1.99B
$7.13M 0.24%
+200,000
New +$6.46M
2018 Q2
0 quarters
ONC icon
56
BeOne Medicines Ltd
ONC
$41.2B
$6.2M 0.21%
40,300
+300
+0.8% +$53.5K
2018 Q1
1 quarter
CTMX icon
57
CytomX Therapeutics
CTMX
$510M
$6M 0.2%
262,400
-72,280
-22% -$1.85M
2015 Q4
10 quarters
NVTA
58
DELISTED
Invitae Corporation
NVTA
$5.97M 0.2%
812,240
-1,327,280
-62% -$8.82M
2015 Q1
13 quarters
SENS icon
59
Senseonics Holdings Inc
SENS
$419M
$5.42M 0.18%
+65,896
New +$4.72M
2018 Q2
0 quarters
SRPT icon
60
Sarepta Therapeutics
SRPT
$1.84B
$4.11M 0.14%
+31,100
New +$2.93M
2018 Q2
0 quarters
EIDX
61
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$3.88M 0.13%
+191,000
New +$4M
2018 Q2
0 quarters
UBX icon
62
DELISTED
Unity Biotechnology
UBX
$3.77M 0.13%
+25,040
New +$3.66M
2018 Q2
0 quarters
ACRS icon
63
Aclaris Therapeutics
ACRS
$506M
$2.13M 0.07%
106,820
– –
2016 Q4
6 quarters
VCEL icon
64
Vericel Corp
VCEL
$2.08B
$1.75M 0.06%
+180,873
New +$2.25M
2018 Q2
0 quarters
ATYR icon
65
aTyr Pharma
ATYR
$18.7M
$1.72M 0.06%
134,642
– –
2017 Q3
3 quarters
OVID icon
66
Ovid Therapeutics
OVID
$439M
$951K 0.03%
121,950
-38,768
-24% -$333K
2017 Q2
4 quarters
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$427K 0.01%
25,800
+5,800
+29% +$88.4K
2017 Q4
2 quarters
IHF icon
68
iShares US Healthcare Providers ETF
IHF
$1.43B
$367K 0.01%
10,435
– –
2018 Q1
1 quarter
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$356K 0.01%
+7,170
New +$347K
2018 Q2
0 quarters
FLXN icon
70
DELISTED
Flexion Therapeutics, Inc.
FLXN
$343K 0.01%
13,260
+3,330
+34% +$86.4K
2018 Q1
1 quarter
SAGE icon
71
DELISTED
Sage Therapeutics
SAGE
$340K 0.01%
+2,170
New +$341K
2018 Q2
0 quarters
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$13.9B
$274K 0.01%
+1,590
New +$260K
2018 Q2
0 quarters
NVRO icon
73
DELISTED
NEVRO CORP.
NVRO
$271K 0.01%
+3,400
New +$282K
2018 Q2
0 quarters
AMED icon
74
DELISTED
Amedisys
AMED
$233K 0.01%
+2,725
New +$200K
2018 Q2
0 quarters
BHC icon
75
Bausch Health
BHC
$2.32B
$208K 0.01%
+8,930
New +$185K
2018 Q2
0 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2018 Portfolio in Review

As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
  • Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
  • Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
  • Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
  • Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
  • Redmile Group opened 27 new positions and closed 12 in Q2 2018.
  • Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.